News
BFRI
0.9259
-1.24%
-0.0116
Weekly Report: what happened at BFRI last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at BFRI last week (1026-1030)?
Weekly Report · 11/02 10:25
Weekly Report: what happened at BFRI last week (1019-1023)?
Weekly Report · 10/26 10:25
Weekly Report: what happened at BFRI last week (1012-1016)?
Weekly Report · 10/19 10:25
Weekly Report: what happened at BFRI last week (1005-1009)?
Weekly Report · 10/12 10:31
Biofrontera Submits Ameluz SNDA For Expanded Actinic Keratosis Use
NASDAQ · 10/08 13:47
Biofrontera submits sNDA to FDA to expand Ameluz indication
TipRanks · 10/08 13:37
Biofrontera Refiles Supplemental New Drug Application For Ameluz Topical Gel To FDA To Treat Actinic Keratoses
Benzinga · 10/08 13:24
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 10/05 21:06
Weekly Report: what happened at BFRI last week (0928-1002)?
Weekly Report · 10/05 10:30
Weekly Report: what happened at BFRI last week (0921-0925)?
Weekly Report · 09/28 10:25
Weekly Report: what happened at BFRI last week (0914-0918)?
Weekly Report · 09/21 10:25
Biotech Stocks In Focus - IMCC +245%, XRTX +12%, SILO, BFRI
NASDAQ · 09/18 19:27
Biofrontera Stock Drops 6% Despite Securing FDA Approval For Ameluz SNDA
NASDAQ · 09/14 14:08
Biofrontera Gains FDA Approval for Ameluz Skin Cancer Use
TipRanks · 09/14 13:58
Biofrontera announces FDA approval of Ameluz supplemental new drug application
TipRanks · 09/14 13:35
Biofrontera Receives FDA Supplemental New Drug Application Approval For Its Ameluz Topical Gel, 10%, In Combination With Photodynamic Therapy Using The BF-RhodoLED Lamp Series For The Treatment Of Superficial Basal Cell Carcinoma In Adults
Benzinga · 09/14 13:31
Weekly Report: what happened at BFRI last week (0907-0911)?
Weekly Report · 09/14 10:31
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Barchart · 09/14 08:26
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 09/11 12:06
More
Webull provides a variety of real-time BFRI stock news. You can receive the latest news about Biofrontera Inc through multiple platforms. This information may help you make smarter investment decisions.
About BFRI
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.